Australia markets closed

    -39.90 (-0.55%)

    +0.0012 (+0.17%)
  • ASX 200

    -37.10 (-0.53%)
  • OIL

    -0.30 (-0.33%)
  • GOLD

    -1.60 (-0.09%)

    -1,237.10 (-3.60%)
  • CMC Crypto 200

    -19.95 (-3.58%)

United States Cardiovascular Devices Market Forecasts 2021-2027: Industry Trends, Growth, Impact of COVID-19, Opportunities, Company Analysis -

·4-min read

DUBLIN, December 06, 2021--(BUSINESS WIRE)--The "United States Cardiovascular Devices Market Forecast 2021-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to's offering.

United States Cardiovascular Devices Market is projected to reach US$ 39.98 Billion by 2027 from US$ 25.34 Billion in 2020, growing with a CAGR of 6.73%

In the United States, cardiovascular diseases or CVDs have long been considered among the prime pain points of the medical industry, with diseases like stroke or IHD (ischemic heart disease) contributing heavily to mortality and disability. Cardiovascular devices are utilised for the diagnosis of heart diseases and treatment of related health problems. Technologies applied in the development of cardiology devices have changed significantly over the past decade, and indications for these devices have expanded.

The prosthetic heart valve is a device inserted in a patient suffering from valvular heart disease, which results in the malfunction of one or more valves present in the human heart. In 2021, according to the American College of Cardiology, there are 5 Million Americans diagnosed with HVD (Heart valve disease) every year.

Due to ageing, HVD mainly affects the older population due to calcium buildup and scarring in the valve cusp. Therefore, the fast growth in the ageing population and the consequent rise in VHD (Valvular heart disease) are significantly driving the demand for prosthetic heart valve in the United States

Factors Driving the United States Cardiovascular Devices Industry

The significant factors driving the growth of the cardiovascular devices market in the United States are the presence of established healthcare infrastructure, rapid technological advancements, increasing burden of cardiovascular diseases, and increased adoption of minimally invasive procedures.

Besides the rising demand for minimally-invasive procedures, especially for peripheral arterial disease, lifestyle changes and technological advancements have expanded the range of peripheral vascular devices in the United States

The continuous development in the cardiovascular field and technological improvements are also expected to drive the market growth of the United States cardiovascular devices.

Impact of COVID-19 Pandemic on Cardiovascular Device Companies

In the first half of 2020, the COVID-19 pandemic has negatively hit the market of cardiovascular devices. The Coronavirus has impacted the production of cardiovascular devices sales as there was a delay of elective procedures. Only those cardiovascular procedures were considered, which were urgent; others have been postponed and delayed since the beginning of the global pandemic.

Another factor negatively affected the market was the decline in the diagnosis of cardiovascular diseases as the healthcare resources were being diverted to Coronavirus patients. However, the monthly revenues of cardiovascular devices companies rebounded in H2 2020 and are back on track

Companies Performance

For instance, in 2020, Abbott restarted its LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company's new Esprit BTK Everolimus-Eluting Resorbable Scaffold System.

This is the leading investigational device exemption (IDE) trial in the United States to assess a completely bio-resorbable stent to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling the first stages of peripheral artery disease (PAD)

Additionally, the key market players such as Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences, Cardinal Health Inc., Medtronic PLC, and GE Healthcare in the United States are developing technologies and novel products to play with the existing products. At the same time, others are partnering and acquiring with other companies trending in the Cardiovascular Devices industry

Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. United States Cardiovascular Devices Market

6. Market Share - United States Cardiovascular Devices Analysis

6.1 By Device Type

6.2 By End Use

7. Device Type - United States Cardiovascular Devices Market

7.1 Cardiac Rhythm Management Device

7.2 Peripheral Vascular Device

7.3 Prosthetic Heart Valves

7.4 Cardiac Assist Devices

7.5 Cardiovascular Surgery Devices

7.6 External Defibrillators

7.7 Clot Management Devices

7.8 Cardiovascular Prosthetic Devices

7.9 Others

8. End User - United States Cardiovascular Devices Market

8.1 Hospitals

8.2 Cardiac Diagnostic Centres

8.3 Ambulatory Surgical Centre

9. Key Players

9.1 Overview

9.2 Recent Development

9.3 Revenue

  • Abbott Laboratories

  • Boston Scientific Corporation

  • Edwards Lifesciences

  • Cardinal Health Inc.

  • Medtronic PLC

  • GE Healthcare

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting